April 5, 2022 -- PathAI and GlaxoSmithKline (GSK) have announced a strategic multiyear partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH).
Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.
The companies said that the partnership will combine GSK's and PathAI's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be integrated into clinical trials.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
